PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi
Sankyo, Inc., the US subsidiary of Daiichi Sankyo Company, Ltd,
announced today that it will merge with its US-based sister
company, Asubio Pharmaceuticals, Inc. As a result, Asubio
Pharmaceuticals, Inc. projects will be integrated into the Daiichi
Sankyo global development organization, led by Mahmoud Ghazzi, MD, PhD.
Asubio Pharmaceuticals' parent company, Asubio Pharma Co., Ltd,
which is based in Japan, will
continue to operate as a wholly owned subsidiary of Daiichi Sankyo
Co., Ltd., with a focus on discovery research.
Asubio Pharmaceuticals, Inc.'s ongoing clinical trial in
patients with acute spinal cord injury, ASBI 603ASCENT Study
(SUN13837) has completed enrollment. An analysis and
dissemination of the data will be managed by Daiichi
Sankyo.
"In line with the Daiichi Sankyo five-year business plan to
optimize our business of delivering innovative treatments to
patients, consolidating the current Asubio US projects under the
company's overall R&D organization helps us streamline our
operations," said Glenn Gormley, MD,
PhD, Senior Executive Officer and Global Head of R&D, Daiichi
Sankyo Company, Ltd., and Executive Chairman and President, Daiichi
Sankyo, Inc.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated
to the creation and supply of innovative pharmaceutical products to
address the diversified, unmet medical needs of patients in both
mature and emerging markets. While maintaining its portfolio of
marketed pharmaceuticals for hypertension, dyslipidemia and
bacterial infections used by patients around the world, the Group
has also launched treatments for thrombotic disorders and is
building new product franchises. Furthermore, Daiichi Sankyo
research and development is focused on bringing forth novel
therapies in oncology and cardiovascular-metabolic diseases,
including biologics. The Daiichi Sankyo Group has created a "Hybrid
Business Model," to respond to market and customer diversity and
optimize growth opportunities across the value chain. For more
information, please visit: www.daiichisankyo.com. Daiichi Sankyo,
Inc., headquartered in Parsippany, New
Jersey, is a member of the Daiichi Sankyo Group. For more
information on Daiichi Sankyo, Inc., please visit www.dsi.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/daiichi-sankyo-inc-and-asubio-pharmaceuticals-inc-merge-300057791.html
SOURCE Daiichi Sankyo, Inc.